Position in FATE
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$150,849
+$95,347 QoQ
Shares Held
125,708
+153.7% QoQ
Ownership
0.108%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2024
4 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in FATE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Headlands Technologies LLC holds $47,716,225 across 76 Biotechnology names. FATE ranks #64 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | IBRX |
ImmunityBio, Inc.
|
397,170 | $3,046,293 | |
| 2 | NKTR |
Nektar Therapeutics
|
28,244 | $2,032,155 | |
| 3 | AGIO |
Agios Pharmaceuticals, Inc.
|
59,257 | $2,004,664 | |
| 4 | VERA |
Vera Therapeutics, Inc.
|
49,223 | $1,980,241 | |
| 5 | MLTX |
MoonLake Immunotherapeutics
|
97,133 | $1,810,559 | |
| 6 | GPCR |
Structure Therapeutics Inc.
|
37,156 | $1,790,919 | |
| 7 | VKTX |
Viking Therapeutics, Inc.
|
49,146 | $1,599,210 | |
| 8 | NVAX |
Novavax Inc
|
189,675 | $1,543,954 |
All Filings in FATE
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $150,849 | 125,708 | Shares | Sole | 2026-05-13 | |
| 2025-06-30 | $55,502 | 49,556 | Shares | Sole | 2025-08-14 | |
| 2024-06-30 | $93,506 | 28,508 | Shares | Sole | 2024-08-07 | |
| 2024-03-31 | $3,904 | 532 | Shares | Sole | 2024-05-07 | |
| No filing history on record for this holder in this stock. | ||||||